Compare Johnson & Johnson (JNJ) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Omnicom Group Inc. — how do they compare? Johnson & Johnson trades at $249.61 (market cap $609.12B), while Omnicom Group Inc. trades at $82.72 (market cap $23.29B). The key difference: Johnson & Johnson is far larger — about 26.2× Omnicom Group Inc.'s market cap, and Omnicom Group Inc. pays the higher dividend (3.92%). Which is the better fit depends on your goals.
| JNJ | OMC | |
|---|---|---|
Market Cap | $609.12B | $23.29B |
Volume | 6,156,228 | — |
Sector | Health | Media |
52-Week High | $267.24 | $85.80 |
52-Week Low | $163.70 | $67.27 |
Enterprise Value | $642.06B | $30.52B |
Dividend Yield | 2.12% | 3.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $251.11, down 0.76% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates and raising full-year guidance. Revenue for 2025 was $94.19 billion with a net income margin of 21.48%. Analysts maintain a Moderate Buy consensus with a $279.33 price target, implying over 11% upside. Recent news highlights institutional buying and the company's robust dividend history.
JNJ's outlook is positive, supported by earnings momentum and a diversified healthcare portfolio. Key opportunities include sustained dividend growth and pipeline strength in pharmaceuticals. Risks involve competitive pressures and execution challenges in the MedTech segment. The stock remains a core holding for long-term investors seeking stability and income.
Omnicom Group (OMC) trades at $82.74, up 1.24% with a bullish technical outlook. The stock shows mixed fundamentals with strong revenue growth to $17.27B in 2025 but negative net income of -$54.50M. Valuation metrics appear reasonable with P/E of 12.16 and P/S of 0.95. Recent corporate developments include major client wins with IBM and Netflix, while maintaining consistent $0.80 quarterly dividends.
Outlook remains cautiously optimistic with analyst consensus target of $105.75 suggesting 28% upside. Key opportunities include AI platform expansion and media network scale, while risks involve intense competition and margin pressure. The stock presents value characteristics with dividend support, though investors should monitor Q2 2026 earnings due July 28 for profitability confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
